Labviva vs BioNTech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Labviva is a digital procurement marketplace for life sciences researchers, connecting labs at academic institutions and biopharma companies with scientific suppliers; raised $22M Series A in 2022;
About
Labviva is a Boston-based life sciences technology company founded in 2017 by Lina Nilsson and Barry Bettman. It operates a digital procurement marketplace purpose-built for scientific researchers at pharmaceutical companies, biotech firms, academic research institutions, and hospitals. The platform aggregates product catalogs from thousands of scientific suppliers — including reagents, lab equipment, consumables, and biological materials — into a unified, searchable interface that integrates directly with institutional procurement and ERP systems such as SAP, Coupa, and Jaggaer. This eliminates the fragmented, email-and-catalog-driven purchasing workflows that dominate scientific procurement.
German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease;
About
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.